AstraZeneca to transfer global rights for Eklira and Duaklir to Covis Pharma

The agreement sharpens the company’s focus on priority medicines in respiratory & immunology portfolio

EMA encourages companies to submit type I variations by end- November

Marketing authorisation holders are advised to submit any type IB variations or groupings of type IBs and type IAs by 3rd December 2021 for a start of procedure in 2021

Sun Pharma's Winlevi available in the US

It is the first U.S. FDA approved novel topical mechanism for acne in nearly 40 years

Mandaviya launches the sixth edition of National Formulary of India (NFI)

The NFI is published to promote the rational use of medicines in the country.

NH TherAguix releases new batch for AGuIX

The release of this batch will secure the supply for hospitals and cancer centres that are involved in the clinical trials managed by the company

Boehringer Ingelheim announces EMA marketing authorisation for spesolimab

Generalized pustular psoriasis is characterized by episodes of widespread eruptions of painful, sterile pustules

Transforming Healthcare Through AI

Indian Pharma Market witnesses rise in volumes and prices in September.

Acute therapies continue to report strong growth compared to chronic ones.

MSD and MPP sign licensing agreement to make molnupiravir affordable

In India, MSD has signed non-exclusive licensing agreements with eight pharma companies.

Novartis receives priority review by U.S. FDA and filing acceptance by EMA for Kymriah

Kymriah, the first-ever FDA-approved CAR-T cell therapy, is currently available in 30 countries in one or more indications